Genomma Lab Internacional SAB de CV

Genomma Lab Internacional SAB de CV

Health CarePharmaceuticals & Biotechnology
  • Price (MXN)19.99
  • Today's Change0.600 / 3.09%
  • Shares traded697.77k
  • 1 Year change22.49%
  • Beta0.5324
Data delayed at least 20 minutes, as of May 25 2020 20:48 BST.
More ▼

Profile data is unavailable for this security.

About the company

Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Company’s product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.

  • Revenue in MXN (TTM)12.91bn
  • Net income in MXN885.84m
  • Incorporated1996
  • Employees1.29k
  • Location
    Genomma Lab Internacional SAB de CVEdificio SamaraAntonio Dovali Jaime no. 70 Piso 2Colonia Santa FeMEXICO, D.F. 01210MexicoMEX
  • Phone+52 5 550810000
  • Fax+52 5 550810000
  • Websitehttp://www.genommalab.com/mx/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Biotoscana Investments SA3.05bn6.58m4.25bn677.001,007.061.4325.351.390.00990.00997.006.980.59442.012.861,097,632.000.12812.290.17963.0646.4950.400.21553.140.83993.240.20440.00-9.4812.83-97.48-38.45----
Ouro Fino Saude Animal Participacoes SA2.63bn203.50m5.32bn1.01k26.142.6417.272.020.91830.918311.879.100.72681.855.02--5.625.607.547.3849.1752.757.738.021.085.580.41225.155.15---32.78------
Genomma Lab Internacional SAB de CV12.91bn885.84m20.32bn1.29k22.802.2619.711.570.85040.850412.528.580.64892.433.5411,354,070.004.450.62126.590.872263.0366.056.860.94471.394.330.41780.007.791.95-31.10-11.79-0.6157--
Hypera SA15.31bn4.54bn73.76bn7.52k16.072.0414.664.821.771.735.9513.920.33221.893.44495,835.409.867.3011.128.8265.5671.4229.6926.512.56--0.191748.64-11.533.544.7228.6112.14--
Data as of May 25 2020. Currency figures normalised to Genomma Lab Internacional SAB de CV's reporting currency: Mexican New Peso MXN

Institutional shareholders

25.27%Per cent of shares held by top holders
HolderShares% Held
Massachusetts Financial Services Co.as of 31 Mar 202056.77m5.42%
Fidelity Management & Research Co. LLCas of 31 Mar 202050.42m4.81%
Capital Research & Management Co. (World Investors)as of 31 Mar 202035.95m3.43%
The Vanguard Group, Inc.as of 30 Apr 202025.48m2.43%
Invesco Advisers, Inc.as of 31 Dec 201922.25m2.12%
BlackRock M�xico SA de CV Asesor en Inversiones Independienteas of 07 May 202022.20m2.12%
Dimensional Fund Advisors LPas of 07 May 202018.18m1.74%
BlackRock Fund Advisorsas of 07 May 202012.45m1.19%
Norges Bank Investment Managementas of 31 Dec 201912.39m1.18%
AllianceBernstein LPas of 31 Mar 20208.77m0.84%
More ▼
Data from 31 Dec 2019 - 21 May 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.